公开(公告)号：US20180092921A1

公开(公告)日：2018-04-05

申请号：US15565866

申请日：2016-04-20

Applicant: UCB Biopharma SPRL

Inventor： Rodger Anthony Allen ,  Francesca Barone ,  William Anthony Fahy ,  Saba Nayar

IPC: A61K31/519 ,  A61K31/4709 ,  A61K9/00

CPC classification number: A61K31/519 ,  A61K9/0014 ,  A61K9/0031 ,  A61K9/0048 ,  A61K9/006 ,  A61K9/0073 ,  A61K31/4709 ,  A61K2300/00

Abstract: N-{(R)-1-[8-Chloro-2-(1-oxypyridin-3-yl)-quinolin-3-yl]-2,2,2-trifluoroethyl}-pyrido[3,2-d]pyrimidin-4-ylamine is effective in the treatment and/or prevention of Sjögren's syndrome.

公开(公告)号：US20190209567A1

公开(公告)日：2019-07-11

申请号：US16099537

申请日：2017-05-15

Applicant: UCB Biopharma SPRL

Inventor： Rodger Anthony Allen ,  Martin John Armstrong ,  Marina Cavazzana ,  Sven Kracker ,  Duncan Philip McHale ,  Andrew Charles Payne

IPC: A61K31/519 ,  A61P37/06

CPC classification number: A61K31/519 ,  A61P37/06

Abstract: N—{(R)-1-[8-Chloro-2-(1-oxypyridin-3-yl)-quinolin-3-yl]-2,2,2-trifluoroethyl}-pyrido[3,2-d]pyrimidin-4-ylamine is effective in the treatment and/or prevention of activated phosphoinositide 3-kinase delta syndrome (APDS).